Motor neuron disease

Degeneration of dopaminergic neuron in Parkinson's disease
#Amyotrophic lateral sclerosis (ALS) #Dementia #Longitude P #MND #Motor neuron disease #Neuroscience

Award transforming drug discovery with AI

The Longitude Prize on ALS is a new £7.5 million ($10.28 million) global challenge prize to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND). Open for entries from 25 June… Read More

#News

Brain physiology
#Amyotrophic lateral sclerosis (ALS) #Artificial intelligence (AI) #Longitude Prize #Machine learning #Motor neuron disease #Neurology #Neuroscience

Third global Longitude Prize to be launched in 2025 focusing on ALS

The Longitude Prize series from Challenge Works will launch the Longitude Prize on amyotrophic lateral sclerosis (ALS) in Spring 2025. The next installment in the prize series follows the success of the Longitude Prize on antimicrobial resistance (AMR), won in 2024 by Sysmex Astrego’s PA-100 AST system, and the Longitude… Read More

#News

Motor neuron disease awareness day
#Amyotrophic lateral sclerosis (ALS) #Motor neuron disease #Neurodegenerative disorders

Six advances in drug discovery for MND / ALS

Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). A new UK research partnership In June, UK charity LifeArc pledged £1.5 million to fund a… Read More

#News #Trending News

Demyelination of neuron
#Genetics / genomics #King's College London #LifeArc #MND #Motor neuron disease #Partnership

UK research partners team up to accelerate MND drug discovery

UK charity LifeArc has pledged £1.5 million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). The new partnership, which will involve scientists from both organisations working closely… Read More

#Editor's Choice #News